The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s Arexvy vaccine, making it the first approved vaccine for respiratory syncytial virus (RSV) in the world. RSV causes mild symptoms similar to a cold but can be deadly to older adults and infants. The vaccine is approved for use in adults aged 60 years and over and was granted expedited approval in November 2021 amid a surge of patients with RSV, flu, and COVID-19 flooding hospitals. Two other RSV vaccines, one by Pfizer and another by Moderna, are currently under review. The vaccine has also been submitted for approval in Europe.
Related Posts
Elsevier authorize the Researchers to access its pay walled journals
The conflict between Elsevier, the world’s biggest publisher of scientific journals, and Germany’s entire university system has dragged on since 2015. However, recently Elsevier has approved continuous access to its paywalled journals for researchers at around 200 German universities and other research institutes that had refused earlier to renew their individual subscriptions. The nationwide deal […]
Advanced models forecast Antarctic ice melt for sea level rise.
The new modeling for Antarctic ice sheet melt employs advanced algorithms that incorporate multiple factors affecting ice sheet behavior. By considering complex variables like ice flow dynamics, ocean interactions, and climate change impacts, the models yield more accurate projections. These insights enhance our understanding of potential sea level rise scenarios, crucial for assessing future climate […]
Hybrid Bacteria: Revolutionizing Disease Treatment
Natural bacteria have a long history of aiding human health, and recent advancements in genetic engineering have led to the creation of hybrid bacteria with enhanced capabilities to treat various diseases. This review covers the characteristics and applications of natural and hybrid bacteria in disease treatment, including obesity, gastrointestinal disorders, and cancer. It also discusses […]